Epigenomics Insights for Personalized Medicine
About Auristone

We are a Multi-Analyte, Pan-Cancer Epigenetics Platform with a focus on Asian diseases and population.

Pan Cancer

We focus on Asian Cancers with demonstrable clinical evidence in Gastric Cancer and meaningful correlations in other cancers

Epigenomic Know-how

We provide actionable insights based on best-in-class pan-cancer epigenomic predictive models that may otherwise be unavailable in genomic information

Platform for novel discoveries

We provide, maintain, and expand our largest Asian epigenomic database that is coupled with in-house analytics to provide a platform for novel discoveries

Our Offering
Epi-Call

Biomarkers – Epigenetic based biomarker for Asian diseases
Our epigenetic profiling test is based on NGS platform and can be bundled with other genomic tests to provide physicians with more actionable information

  • We developed the Alternate Promoter Burden (APB) Score, an independent biomarker that predicts patient response for immunotherapy for Gastric cancer
  • We also run parallel programmes to expand coverage of APB to other cancers and other treatment options
  • We welcome both commercial partnerships and co-development partnerships for new biomarker discovery
Epi-Tome

Drug targets – Candidates based on epigenomic pathways and insights
Epigenetic profiling reveals new mechanisms and pathways and provides insights that can be exploited for novel treatments

  • We discovered potential candidates for Mes-GC subtypes through epigenomic profiling and demonstrated viability through POC experimentations
  • We have a pipeline of potential targets suitable for co-development
  • We welcome co-development partnerships for new drug target discovery
Our Founding Team
Chew Jing Ming
Chew Jing Ming

CEO & co-Founder

More than 10 years medtech experience across public/private and different functions; proven experience in growing teams from scratch till beyond Series B

  • Prev. COO of a Series B gastric cancer Medtech startup
  • MBA (Healthcare Management), NUS, 2017
  • Singapore Stanford Biodesign Global Fellow 2013
  • B.Eng. in Biomedical Engineering, Imperial College London, 2011
  • Mentor for Singapore Biodesign Fellowship
  • Received the reddot award 2020 (best of the best) for Product Design
Professor Patrick Tan Boon Ooi (MD, PhD)
Professor Patrick Tan Boon Ooi (MD, PhD)

co-Founder

Prolific thought leader in epigenomics and cancer biology; developed and optimized subgroup specific treatments for gastric cancer patients based on molecular subtypes

  • Executive Director, Genome Institute of Singapore, A*STAR
  • Professor, Duke-NUS Medical School, Singapore
  • Director, Duke-NUS Genome Biology Facility
  • Director, SingHealth Duke-NUS Institute of Precision Medicine
  • Received awards include:
    AACR Team Science Award (Team Leader) 2018, Japanese Cancer Association International Award 2016, President’s Science Award (Team) 2015, Chen New Investigator Award, Human Genome Organization 2013, American Society for Clinical Investigation 2013

Professor Teh Bin Tean (MD, PhD)
Professor Teh Bin Tean (MD, PhD)

co-Founder

Distinguished expert in medical (epi)genetics for Asian-prevalent cancers and drug discovery; completed the world’s-first Durian genetic map and unravelled the gene that causes its pungent smell

  • Deputy Director (Research), National Cancer Centre Singapore
  • Deputy Director (Global Relations), SingHealth Duke-NUS Institute of Precision Medicine (PRISM)
  • Professor, Duke-NUS Medical School, Singapore
  • Principal Investigator, Lab of Cancer Epigenome, National Cancer Centre Singapore
  • Received awards include:

    AACR Team Science Award 2018, President’s Science Award (Team) 2015, American Society for Clinical Investigation 2014

Literature

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

Authors: Raghav Sundar, Kie-Kyon Huang, Vikrant Kumar, Kalpana Ramnarayanan, Deniz Demircioglu, Zhisheng Her, Xuewen Ong, Zul Fazreen Bin Adam Isa, Manjie Xing, Angie Lay-Keng Tan, David Wai Meng Tai, Su Pin Choo, Weiwei Zhai, Jia Qi Lim, Meghna Das Thakur, Luciana Molinero, Edward Cha, Marcella Fasso, Monica Niger, Filippo Pietrantonio, Jeeyun Lee, Anand D Jeyasekharan, Aditi Qamra, Radhika Patnala, Arne Fabritius, Mark De Simone, Joe Yeong, Cedric Chuan Young Ng, Sun Young Rha, Yukiya Narita, Kei Muro, Yu Amanda Guo, Anders Jacobsen Skanderup, Jimmy Bok Yan So, Wei Peng Yong, Qingfeng Chen, Jonathan Göke, Patrick Tan

Gut. 2021;0:1–12. doi:10.1136/gutjnl-2021-324420

In this study, we report an association between alternate promoter burden (APB) and the tumor microenvironment in cancers, leading to immune evasion and resistance towards cancer immunotherapy.


Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers

Authors: Raghav Sundar, Elizabeth C. Smyth, Siyu Peng, Joe P. S. Yeong, Patrick Tan

Front. Oncol., 10:763. doi: 10.3389/fonc.2020.0076315

In this review, we discuss on the latest immune checkpoint inhibitor clinical trials and predictive biomarkers for gastroesophageal cancers.


A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters

Authors: Deniz Demircioğlu, Engin Cukuroglu, Martin Kindermans, Tannistha Nandi, Claudia Calabrese, Nuno A Fonseca, André Kahles, Kjong-Van Lehmann, Oliver Stegle, Alvis Brazma, Angela N Brooks, Gunnar Rätsch, Patrick Tan, Jonathan Göke

Cell. 2019 Sep 5;178(6):1465-1477.e17. doi: 10.1016/j.cell.2019.08.018

In this study, we infer active promoters using RNA-seq data from 18,468 cancer samples across 42 cancer types and report that alternative promoters are common biomarkers that are applicable to many cancer types.


Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

Authors: R Sundar, K K Huang, A Qamra, K-M Kim, S T Kim, W K Kang, A L K Tan, J Lee, P Tan

Ann Oncol. 2019 Mar 1;30(3):424-430. doi: 10.1093/annonc/mdy550

In this study, we demonstrate alternate promoter utilization is a potential mechanism of resistance to cancer immunotherapy, and a novel predictive biomarker for immunotherapy treatment outcome.


Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma

Authors: Aditi Qamra, Manjie Xing, Nisha Padmanabhan, Jeffrey Jun Ting Kwok, Shenli Zhang, Chang Xu, Yan Shan Leong, Ai Ping Lee Lim, Qianqao Tang, Wen Fong Ooi, Joyce Suling Lin, Tannistha Nandi, Xiaosai Yao, Xuewen Ong, Minghui Lee, Su Ting Tay, Angie Tan Lay Keng, Erna Gondo Santoso, Cedric Chuan Young Ng, Alvin Ng, Apinya Jusakul, Duane Smoot, Hassan Ashktorab, Sun Young Rha, Khay Guan Yeoh, Wei Peng Yong, Pierce K H Chow, Weng Hoong Chan, Hock Soo Ong, Khee Chee Soo, Kyoung-Mee Kim, Wai Keong Wong, Steven G Rozen, Bin Tean Teh, Dennis Kappei, Jeeyun Lee, John Connolly, Patrick Tan

Cancer Discov. 2017 Jun;7(6):630-651. doi: 10.1158/2159-8290.CD-16-1022. Epub 2017 Mar 20

In this study, we apply epigenomic tools to profile promoter landscape of gastric cancer. Tumor-specific promoters were reported to reduce tumor antigenicity, contributing to cancer immunoediting and immune evasion.


Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

Authors: Wen Fong Ooi, Manjie Xing, Chang Xu, Xiaosai Yao, Muhammad Khairul Ramlee, Mei Chee Lim, Fan Cao, Kevin Lim, Deepak Babu, Lai-Fong Poon, Joyce Lin Suling, Aditi Qamra, Astrid Irwanto, James Qu Zhengzhong, Tannistha Nandi, Ai Ping Lee-Lim, Yang Sun Chan, Su Ting Tay, Ming Hui Lee, James O. J. Davies, Wai Keong Wong, Khee Chee Soo, Weng Hoong Chan, Hock Soo Ong, Pierce Chow, Chow Yin Wong, Sun Young Rha, Jianjun Liu, Axel M. Hillmer, Jim R. Hughes, Steve Rozen, Bin Tean Teh, Melissa Jane Fullwood, Shang Li, Patrick Tan

Nat Commun 7, 12983 (2016). https://doi.org/10.1038/ncomms12983

In this study, we apply epigenomic tools to reveal super-enhancer landscape of gastric cancer. Super-enhancers contribute to aberrant cancer gene expression and tumorigenesis.


Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements

Authors: Masafumi Muratani, Niantao Deng, Wen Fong Ooi, Suling Joyce Lin, Manjie Xing, Chang Xu, Aditi Qamra, Su Ting Tay, Simeen Malik, Jeanie Wu, Ming Hui Lee, Shenli Zhang, Luke Lin Chuen Tan, Huihoon Chua, Wai Keong Wong, Hock Soo Ong, London Lucien Ooi, Pierce Kah-How Chow, Weng Hoong Chan, Khee Chee Soo, Liang Kee Goh, Steve Rozen, Bin Tean Teh, Qiang Yu, Huck Hui Ng, Patrick Tan

Nat Commun 5, 4361 (2014). https://doi.org/10.1038/ncomms5361

In this study, we demonstrate the feasibility of using Nano-ChIPSeq technology to profile epigenetic markers from clinical tumour samples to identify cancer specific regulatory elements.


Our Partners
Contact
If you’d like to join us or partner with us, please reach out and we will get back to you at the earliest!
Join our mailing list to be kept updated of the latest news!
Address

LaunchPad @ one-north
73 Ayer Rajah Crescent #02-19
Singapore 139952

 

Email

enquiry@auristone.com

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google